Published in Biotech Business Week, July 25th, 2005
The trial results failed to demonstrate a statistically significant benefit for any of the three coprimary endpoints. The trials met the prespecified safety endpoint by demonstrating no significant difference in mortality between the enoximone and placebo groups.
Based on these results, the company will terminate development of enoximone capsules and dedicate all resources to the development of its two other late-stage clinical programs, ambrisentan for the treatment of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.